Avalo Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $59,000 | $441,000 | $1.9M | $18.1M | $5.4M |
| Operating income | -$72.9M | -$68.5M | -$27.4M | -$37.4M | -$82.1M |
| Cost of revenue | — | — | $1.3M | $3.4M | $1.5M |
| Cash from operations | -$51.5M | -$49.1M | -$30.7M | -$26.8M | -$70.9M |
| Capital expenditure | — | — | $0 | $95,000 | $113,000 |
| Free cash flow | — | — | -$30.7M | -$26.8M | -$71.0M |
| Share repurchases | — | — | $3.6M | — | — |
| Impairments | — | $0 | $3.9M | $0 | — |
| Total assets | $116.5M | $150.7M | $21.0M | $33.4M | $80.2M |
| Total liabilities | $33.4M | $17.7M | $13.7M | $44.3M | $57.1M |
Shares outstanding 52.6M · Free float 90.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.